Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saturno II vs Vigadexa for Post-Phacoemulsification Ocular Inflammation
NCT03580473Phase 2Completed
- Sponsor
- EMS
- Start
- Feb 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ocular inflammation (2 arms), sponsored by EMS. Primary endpoint: Control of ocular inflammation post-phacoemulsification at 16 days. Started Feb 2020; status: completed.
02
Conditions
ocular inflammation
Beyond the preview
Go deeper on NCT03580473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03580473.